Electroencephalographic Biomarker to Predict Acute Post-operatory Cognitive Dysfunction

Sponsor
University of Chile (Other)
Overall Status
Recruiting
CT.gov ID
NCT04214496
Collaborator
Masimo Corporation (Industry)
106
2
14.9
53
3.5

Study Details

Study Description

Brief Summary

Acute post-operatory cognitive dysfunction states are one of the most important complications in older patients after surgery. Two acute cognitive dysfunctions have been described: postoperative delirium (PD) and postoperative subsyndromal delirium (PSSD). Patients who develop delirium, both as a complete or incomplete syndrome, have poor long-term outcomes, such as longer length of hospital stay, institutionalization at discharge, and even higher mortality, and consequently, the human and economic costs significantly increase for the health system. Here the research team will use an observational cohort, investigator blinded in two-center with a primary endpoint to validate the relative alpha power ratio as a predictive biomarker of postoperative cognitive dysfunctions.

Condition or Disease Intervention/Treatment Phase
  • Device: Sedline

Detailed Description

Acute post-operatory cognitive dysfunction states are one of the most important complications in older patients after surgery. Two acute cognitive dysfunctions have been described: postoperative delirium (PD) and postoperative subsyndromal delirium (PSSD). In previous reports, the incidence of PD in older patients is between 10% to 30%, while PSSD is more frequent 30% to 50%. Patients who develop delirium, both as a complete or incomplete syndrome, have poorer long-term outcomes, such as longer length of hospital stay, institutionalization at discharge, and even higher mortality, and consequently, the human and economic costs significantly increase for the health system.

An early diagnostic and prevention of delirium are the key points to decrease the poor long-term outcomes and health costs. The diagnosis requires cognitive testing to elucidate functional patients' status before and after surgery. The need for a biomarker that may predict the occurrence of PD and PSSD and allow the selection of patients who need prevention strategies is a primary research field.

Here the research team will use an observational cohort, investigator blinded in two-center with a primary endpoint to validate the relative alpha power ratio as a predictive biomarker of postoperative cognitive dysfunctions.

To calculate the sample size, the investigators used values obtained from a previous work in a cohort of 30 patients and decided to compare the prediction ability of MoCA and alpha power ratio. ROC curves and their AUC were used to calculate the prediction ability of MoCA and alpha power ratio. Thus, a sample size of 425 patients was calculated considering an AUC of MoCA = 0.786 and AUC of alpha power = 0.895, a two-tailed test, an alpha error of 0.05 and a power of 0.8 and considering a 25% loss. Investigators consider this study as a pilot validation trial to establish the utility and the capacity of the EEG biomarker for predicting PD and PSSD, the research team aims to include the 25% of the total sample. This yields the need for 106 patients for this preliminary trial.

Study Design

Study Type:
Observational
Anticipated Enrollment :
106 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Electroencephalographic Biomarker to Predict the Development of Acute Post-operatory Cognitive Dysfunction States: a Protocol of an Observational Study in a Cohort of Patients From Two Centers
Actual Study Start Date :
Jan 4, 2021
Anticipated Primary Completion Date :
Jan 4, 2022
Anticipated Study Completion Date :
Apr 4, 2022

Arms and Interventions

Arm Intervention/Treatment
Postoperative Delirium Risk Patients

Preoperative cognitive function testing- EEG monitorization during surgery - Postoperative function testing

Device: Sedline
Intraoperative EEG monitorization

Outcome Measures

Primary Outcome Measures

  1. Delirium and Subsyndromal Delirium [5 Postoperative days]

    Incidence of Delirium and Subsyndromal Delirium in the cohort

Secondary Outcome Measures

  1. Death [Perioperative period]

    Number of deceased patients

  2. Delirium Severity [5 Postoperative days]

    Delirium severity assessed by Cognitive Assessment Method - Severity

  3. Delirium Duration [Perioperative period]

    Duration of delirium during the perioperative period

  4. Need for Mechanical Ventilation assistance [Perioperative period]

    Number of patients that needed mechanical ventilation

  5. Reintervention [Perioperative period]

    Number of patients that needed another surgery after primary intervention

  6. Unanticipated ICU hospitalization [Perioperative period]

    Number of patients that needed unanticipated intensive care unit (ICU) care

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Age ≥ 60 years old

  • Scheduled for high-risk elective surgery

  • Need for at least 3 days of hospital stay

  • Surgery performed under general anesthesia

  • Written informed consent for participation in the trial

Exclusion Criteria:
  • Patients with preoperative delirium or dementia

  • Patients using neuroleptics drug during the past 6 months

  • Patients with a history of encephalopathy, psychosis, stroke or brain trauma with neurologic sequels

  • The use of ketamine or dexmedetomidine during surgery

  • Emergency surgery

  • Mechanical ventilation during the 72 after surgery

  • Analphabetism

  • Patients who do not talk Spanish

  • Patients included in another clinical trial

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Clinico Universidad de Chile Santiago Chile 8380456
2 Instituto Nacional del Cancer Santiago Chile

Sponsors and Collaborators

  • University of Chile
  • Masimo Corporation

Investigators

  • Study Chair: José I. Egaña, M.D./Ph.D., University of Chile

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
José Ignacio Egaña Tomic, Director, University of Chile
ClinicalTrials.gov Identifier:
NCT04214496
Other Study ID Numbers:
  • ID19I10345
First Posted:
Jan 2, 2020
Last Update Posted:
Jun 21, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by José Ignacio Egaña Tomic, Director, University of Chile
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 21, 2021